Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
Lee Hallman is a freelance writer for credit cards and travel rewards at Forbes Advisor. She is a source of information and inspiration for readers looking to navigate the world of travel with savvy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results